DOT1L inhibition reprograms innate immunity to potentiate immunomodulatory drug responses in multiple myeloma
Open Access
- 21 July 2025
- journal article
- Published by Elsevier in Cancer Letters
- Vol. 631, 217941
Abstract
No abstract availableKeywords
Funding Information
- Northern Advancement Center for Science and Technology (2022)
- Princess Takamatsu Cancer Research Fund
- Japan Society for the Promotion of Science (22H02925)
- Japan Society for the Promotion of Science (19K17836)
- Japan Society for the Promotion of Science (23K24186)
- Japan Society for the Promotion of Science (19H03518)
- Japan Society for the Promotion of Science (23K15329)
- Japan Society for the Promotion of Science (21K15556)
- Akiyama Life Science Foundation (2023)
This publication has 54 references indexed in Scilit:
- Therapeutic targeting of EP300/CBP by bromodomain inhibition in hematologic malignanciesCancer Cell, 2023
- Inhibition of the CtBP complex and FBXO11 enhances MHC class II expression and anti-cancer immune responsesCancer Cell, 2022
- Immune checkpoint inhibition improves antimyeloma activity of bortezomib and STING agonist combination in Vk*MYC preclinical modelClinical and Experimental Medicine, 2022
- Cytoplasmic DNA: sources, sensing, and role in aging and diseaseCell, 2021
- Defining a Cancer Dependency MapCell, 2017
- HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implicationsLeukemia, 2017
- MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantationLeukemia, 2017
- The upstreams and downstreams of H3K79 methylation by DOT1LChromosoma, 2016
- Bat3 facilitates H3K79 dimethylation by DOT1L and promotes DNA damage‐induced 53BP1 foci at G1/G2 cell‐cycle phasesThe EMBO Journal, 2012
- Interleukin-6 sensitizes multiple myeloma cell lines for apoptosis induced by interferon-αExperimental Hematology, 2000